Mylan Pharmaceuticals Inc. has launched voriconazole for oral suspension (40 mg/ml), an antifungal medicine.


Mylan Pharmaceuticals, voriconazole for oral suspension, antifungal medicine, triazole antifungal drug, Vfend for Oral Suspension, generic version, Pfizer, marketing exclusivity, Heather Bresch






































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Mylan releases generic of Vfend

September 30th, 2013

PITTSBURGH – Mylan Pharmaceuticals Inc. has launched voriconazole for oral suspension (40 mg/ml), an antifungal medicine.

Mylan said Monday that its product is the first generic version of Pfizer's Vfend for Oral Suspension.

Voriconazole for oral suspension (40 mg/ml), a triazole antifungal drug, had U.S. sales of about $17.1 million for the 12 months ended June 30, according to IMS Health data reported by Mylan.

Mylan noted that it was was the first company to have filed a substantially complete Abbreviated New Drug Application (ANDA) containing a Paragraph IV patent certification for voriconazole for oral suspension (40 mg/ml) and, after receiving final approval from the Food and Drug Administration, was awarded 180 days of marketing exclusivity.

"Mylan's launch of voriconazole for oral suspension, 40 mg/ml, supports the company's mission to expand access to high-quality medicine by bringing to market the first, low-cost generic version of this product," stated Mylan chief executive officer Heather Bresch. "We are committed to continuing to develop, manufacture and market a broad range of generic pharmaceuticals, including specialty, niche products such as this one."

Advertisement